In a prospective observation study of 601 patients with systemic sclerosis (SSc), the use of vasodilators (including calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors and/or angiotension II receptor blockers) was associated with a reduced incidence of ventricular arrhythmias (hazard ratio (HR) 0.28, 95% CI 0.09–0.90). In the same multi-variant Cox regression analysis, low-dose acetylsalicylic acid (ASA) (≤325 mg daily) was associated with a reduced incidence of cardiac blocks and/or Q waves and/or pacemaker implantation (HR 0.46, 95% CI 0.24–0.87).
References
Original article
Valentini, G. et al. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-215486 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McHugh, J. Protecting against myocardial disease in SSc. Nat Rev Rheumatol 15, 574 (2019). https://doi.org/10.1038/s41584-019-0299-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0299-2
